Literature DB >> 15915001

Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase.

Ibrahim F Benter1, Mariam H M Yousif, Andrew J Hollins, Sioned M Griffiths, Saghir Akhtar.   

Abstract

Contribution of receptor tyrosine kinase activation to development of diabetes-induced renal artery dysfunction is not known. We investigated the ability of a chronic administration of genistein, a broad-spectrum inhibitor of tyrosine kinases (TKs), and AG1478, a specific inhibitor of epidermal growth factor receptor (EGFR) TK activity, to modulate the altered vasoreactivity of isolated renal artery ring segments to common vasoconstrictors in streptozotocin-induced diabetes. In diabetic renal artery, the vasoconstrictor responses induced by norepinephrine, endothelin-1 and angiotensin II were significantly increased. Inhibition of TKs or the EGFR pathway did not affect the agonist-induced vasoconstrictor responses in the non-diabetic control animals. However, inhibition of TKs by genistein or EGFR TK by AG1478 treatment produced a significant normalization of the altered agonist-induced vasoconstrictor responses without affecting blood glucose levels. Treatment with diadzein, an inactive analogue of genistein, did not affect the vasoconstrictor responses in the diabetic animals. Western blotting showed that phosphorylated EGFR protein levels were increased in vehicle-treated diabetic animals. In renal arteries from AG1478-treated diabetic animals, EGFR protein levels were similar to non-diabetic control animals. These data suggest that activation of TK-mediated pathways, including the EGFR TK signalling pathway, are involved in the development of diabetic vascular dysfunction in the renal artery. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15915001     DOI: 10.1159/000085904

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  11 in total

1.  Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

Authors:  Hui Ning; Ming Liu; Lina Wang; Yang Yang; Nan Song; Xiaoxiong Xu; Jin Ju; Gening Jiang
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  Angiotensin-(1-7) inhibits epidermal growth factor receptor transactivation via a Mas receptor-dependent pathway.

Authors:  Saghir Akhtar; Mariam H M Yousif; Gursev S Dhaunsi; Bindu Chandrasekhar; Omama Al-Farsi; Ibrahim F Benter
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Diabetic cardiomyopathy: Role of epidermal growth factor receptor tyrosine kinase.

Authors:  Zheng Xu; Lu Cai
Journal:  J Mol Cell Cardiol       Date:  2015-04-10       Impact factor: 5.000

4.  Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor.

Authors:  Weijing Cai; John C He; Li Zhu; Changyong Lu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-05       Impact factor: 11.205

5.  The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction.

Authors:  Saghir Akhtar; Ibrahim Fadil Benter
Journal:  Bioimpacts       Date:  2013-01-26

6.  Activation of ErbB2 and Downstream Signalling via Rho Kinases and ERK1/2 Contributes to Diabetes-Induced Vascular Dysfunction.

Authors:  Saghir Akhtar; Mariam H M Yousif; Gursev S Dhaunsi; Fatma Sarkhouh; Bindu Chandrasekhar; Sreeja Attur; Ibrahim F Benter
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

7.  Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury.

Authors:  Saghir Akhtar; Mariam H M Yousif; Bindu Chandrasekhar; Ibrahim F Benter
Journal:  PLoS One       Date:  2012-06-13       Impact factor: 3.240

8.  A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation.

Authors:  Henry J Tsai; Shan-Yen Chou
Journal:  J Biomed Sci       Date:  2009-07-30       Impact factor: 8.410

9.  RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.

Authors:  Ibrahim F Benter; Fawzi Babiker; Ibrahim Al-Rashdan; Mariam Yousif; Saghir Akhtar
Journal:  J Diabetes Res       Date:  2013-08-27       Impact factor: 4.011

10.  Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.

Authors:  Saghir Akhtar; Bindu Chandrasekhar; Sreeja Attur; Gursev S Dhaunsi; Mariam H M Yousif; Ibrahim F Benter
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.